Hematology News

Bayer and Janssen Research and Development announced FDA approval for a label update of rivaroxaban treatment for venous thromboembolism.

Warfarin use was associated with a significantly lower rate of cancer incidence across a broad range of malignancies among adults over the age of 50 years, compared with nonuse, according to new research published in JAMA Internal Medicine.

ASH today announced the election of three new members to its executive committee.

Six months of hydroxyurea therapy detrimentally effected spermatogenesis in men with sickle cell anemia, according to a small prospective study published in Blood.

A joint policy statement released by the AAP Sections on Hematology/Oncology and Allergy and Immunology emphasizes the importance of donating cord blood to public banks for later use in hematopoietic stem cell transplantation to treat children with malignancies, blood disorders, immune deficiencies and metabolic disorders.

The FDA granted breakthrough therapy designation to valoctocogene roxaparvovec for the treatment of patients with hemophilia A.

Integrating palliative care with hematopoietic stem cell transplantation improved symptoms of PTSD and depression among patients with hematologic malignancies, according to the results of a randomized clinical trial.

The FDA has granted priority review to six drugs under investigation for a variety of hematologic and oncologic indications.

Hydroxyurea did not increase the risk for malaria infection in children with sickle cell anemia who live in malaria-endemic regions of Uganda, according to the results of a randomized, double-blind clinical trial published in Blood.

Men who received red blood cell transfusions from women who had ever been pregnant appeared to have an increased risk for death, according to results of a large, retrospective study published in JAMA.